Novavax Inc. today announced that health leaders in Spain, Italy, and France released updated recommendations expanding the use of the protein-based Nuvaxovid™(NVX-CoV2373) COVID-19 vaccine in people aged 18 and older (adults) in their respective countries.
As of January 5, 2023, Novavax’ COVID-19 vaccine is authorized for use as an adult booster in more than 35 countries, and several other countries have policy recommendations allowing the use of the vaccine as a booster dose.
Furthermore, Novavax’ COVID-19 vaccine is also authorized for use in adolescents aged 12 through 17 in more than 30 markets, including the U.S., member states in the European Union, and the United Kingdom.
Previously, Novavax announced a potential solution for the next flu season.
The company initiated a phase 2 clinical trial for its COVID-19-Influenza Combination in older adults aged 50 through 80.
Stanley C. Erck, President and Chief Executive Officer, Novavax, stated in a press release issued on December 30, 2022, “We believe that like influenza, COVID-19 will also be seasonal moving forward and that there is room in the market for new alternatives to provide better protection against the impact of influenza, particularly in older adults, and to explore the potential to combine this with protection from COVID.”
Novavax, Inc. is a biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases.
Disclosures: This is not paid content and no industry conflicts of interest.
Please not reproduce this content in part or in whole without permission. Share the page URL which directs to the original content.
Precision Vax LLC websites do not provide medical advice, diagnosis, treatment, or prescriptions. Read our terms of use for more info.
